Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.

Lin, Hui Xian Jaime; Cho, Sanda; Meyyur Aravamudan, Veeraraghavan; Sanda, Hnin Yu; Palraj, Raj; Molton, James S; Venkatachalam, Indumathi

Lin, Hui Xian Jaime; Cho, Sanda; Meyyur Aravamudan, Veeraraghavan; Sanda, Hnin Yu; Palraj, Raj; Molton, James S; Venkatachalam, Indumathi.

Afiliação

Lin HXJ; Department of Medicine, Woodlands Health Campus, Singapore, Singapore. jaimelin06@gmail.com.
Cho S; Department of General Medicine, Warrington and Halton Hospitals NHS Trust, Warrington, UK.
Meyyur Aravamudan V; Department of Medicine, Woodlands Health Campus, Singapore, Singapore.
Sanda HY; Department of Acute Medicine, Queens Hospital, Romford, England, UK.
Palraj R; Division of Infectious Diseases, Mayo Clinic College of Medicine, Rochester, USA.
Molton JS; Department of Infectious Disease, Western Health, Footscray, Australia.
Venkatachalam I; Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore.

Infection ; 49(3): 401-410, 2021 Jun.

Article em En | MEDLINE | ID: mdl-33389708

Assuntos

Monofosfato de Adenosina/análogos & derivados; Alanina/análogos & derivados; Antivirais/uso terapêutico; Tratamento Farmacológico da COVID-19; Monofosfato de Adenosina/uso terapêutico; Alanina/uso terapêutico; Animais; COVID-19/epidemiologia; Humanos; SARS-CoV-2/efeitos dos fármacos; Fatores de Tempo; Resultado do Tratamento

Palavras-chave

COVID-19; Hui Xian Jaime Lin and Sanda Cho shared the first authorship; Remdesivir; SAR-CoV-2

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Monofosfato de Adenosina / Alanina / Tratamento Farmacológico da COVID-19 Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google